NEW YORK, Sept. 6 (GenomeWeb News) - Dutch biotech TNO and Mitsubishi Pharma of Japan have entered into a technology development collaboration for siRNA-based target validation studies.
Under the terms of the agreement, TNO will use its siRNA knockdown technology and disease models to further characterize a set of Mitsubishi's proprietary disease targets.
Financial terms of the agreement were not disclosed.